Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Antiasthmatic Effect of YM976, a Novel PDE4 Inhibitor, in Guinea Pigs

Motonori Aoki, Satoshi Yamamoto, Miki Kobayashi, Keiko Ohga, Hiroyuki Kanoh, Keiji Miyata, Kazuo Honda and Toshimitsu Yamada
Journal of Pharmacology and Experimental Therapeutics April 2001, 297 (1) 165-173;
Motonori Aoki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Yamamoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miki Kobayashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keiko Ohga
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroyuki Kanoh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keiji Miyata
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuo Honda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshimitsu Yamada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

YM976 is a novel and specific phosphodiesterase 4 inhibitor. In our previous report, we indicated that YM976 has less emetogenicity, a major adverse effect of PDE4 inhibitors, than rolipram. In the present study, we examined the antiasthmatic effects of YM976 in guinea pigs. YM976 orally administered exhibited inhibition of antigen-induced bronchoconstriction, airway plasma leakage, airway eosinophil infiltration, and airway hyperreactivity (AHR), with ED50values of 7.3, 5.7, 1.0, and 0.52 mg/kg, respectively. Rolipram also dose dependently suppressed these responses. Prednisolone suppressed eosinophil infiltration and AHR, whereas it failed to inhibit bronchoconstriction and plasma leakage. Theophylline moderately suppressed bronchoconstriction and edema, but neither eosinophil infiltration nor AHR. YM976 suppressed the peroxidase activity in the bronchoalveolar lavage fluid, and elevated the intracellular peroxidase activity and cAMP contents of infiltrated cells, suggesting that YM976 inhibited not only the infiltration but also the activation of leukocytes. In vitro studies revealed that YM976 potently suppressed eosinophil activation (EC30 = 83 nM), and exerted a little relaxation on LTD4-precontracted tracheal smooth muscle (EC50 = 370 nM). Rolipram exhibited a potent tracheal relaxation activity (EC50 = 50 nM). In vivo studies indicated that the inhibitory effect of YM976 on LTD4-induced bronchospasm was marginal even at 30 mg/kg p.o., although rolipram significantly inhibited the bronchospasm at the same dose. These results suggested that YM976, unlike rolipram, showed the inhibition of antigen-induced airway responses due to anti-inflammatory effects, but not to direct tracheal relaxation. In conclusion, YM976 may have potential therapeutic value in the treatment of asthma through its anti-inflammatory activities.

Bronchial asthma is characterized by reversible airway obstruction, inflammation, and airway hyperresponsiveness. One of the most important therapies for asthma is the inhibition of bronchoconstriction induced by antigen. Treatment with bronchodilators such as theophylline, which is a nonselective phosphodiesterase (PDE) inhibitor, is recommended in almost all cases of asthma.

Eosinophils, which are mainly related the inflammation of asthma, contain PDE4 isozyme, and inhibition of this enzyme is associated with the increase of the intracellular cAMP level and causes suppression of the activities of eosinophils (Giembycz and Dent, 1992). Tracheal smooth muscle cells contain PDE3 and PDE4 isozymes that have an important function as modulators of contractility (Bernareggi et al., 1999). Based on the putative role of cAMP in inflammatory cells and airway smooth muscle, PDE4 has been identified as a molecular target for novel antiasthmatic agents (Barnette, 1999).

YM976, 4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one, is a novel, specific, and potent PDE4 inhibitor (Aoki et al., 2000b) with a chemical structure different from that of rolipram-like compounds. YM976 has a potent inhibitory activity for PDE4 (IC50 = 2.2 nM) as well as showing no inhibition against other PDE isozymes at 3 pM. Interestingly, YM976 showed anti-inflammatory activities in ferrets at doses causing none of the emesis that is a main adverse effect of PDE4 inhibitors (Aoki, 2000a). Thus, in YM976, the anti-inflammatory effects are dissociated from emetogenicity.

Antigen inhalation to the sensitized guinea pigs produced immediate bronchoconstriction, airway plasma leakage, airway hyperreactivity, and inflammatory cell infiltration. These events in guinea pigs have been used for the assessment of various candidates of antiasthmatic agents. In the present studies, whose aim was to throw light on the potential of YM976 as an antiasthmatic drug, we evaluated its effects on antigen-induced airway responses in guinea pigs. Additionally, the effect of YM976 on the activation of infiltrated leukocytes was examined in vivo. Its in vitro effects were also evaluated in guinea pig eosinophils and tracheal preparations. In some experiments, we compared the effects of YM976 with those of the other PDE4 inhibitors rolipram and RP73401, and those of the existing antiasthmatic agents prednisolone and theophylline.

Materials and Methods

Animals.

Male Hartley guinea pigs weighing 500 to 700 g were purchased from SLC (Hamamatsu, Japan) or Charles River Japan (Atsugi, Japan). The animals were maintained in ordinary animal cages in a constant 12-h light/dark cycle. Food and water were available ad libitum.

Chemicals.

YM976, (±)-rolipram, and RP73401 were synthesized by the Department of Chemistry, Yamanouchi Pharmaceutical Co. Ltd. (Tsukuba, Japan). Theophylline and prednisolone were purchased from Sigma Chemical Co. (St. Louis, MO). In in vitro experiments, all compounds were dissolved in dimethylsulfoxide (DMSO), and the final concentration of DMSO was less than 0.1%. In in vivo experiments, all compounds were suspended in 0.5% methylcellulose solution, and were administered orally at a volume of 3 ml/kg to animals that were fasted for 16 h. Animals in ovalbumin (OA) and saline groups received only the vehicle.

The reagents and chemicals used were pyrilamine maleate salt, histamine, acetylcholine (ACh), cytochrome c, superoxide dismutase, fMLP, OA grade V or VI, EDTA, Hanks' balanced salt solution without calcium chloride or magnesium sulfate, Krebs-Henseleit buffer, galamine, DMSO, and urethane were purchased from Sigma Chemical Co. Methylcellulose (TC-5E) was purchased from Shin-Etsu Chemical Co. (Tokyo, Japan), HEPES from Life Technologies (Rockville, MD), LTD4 from Funakoshi Co., Ltd. (Tokyo, Japan), diethyl ether and chloroform from Kanto Chemicals (Tokyo, Japan), aluminum hydroxide (Alum, Imject) from Pierce (Rockford, IL), heparin from Shimizu Seiyaku (Shimizu, Japan), pentobarbital sodium from Nacalai Tesque (Kyoto, Japan), and Diff-Quik from International Reagents Corp. (Kobe, Japan).

Sensitization of Guinea Pigs.

Male Hartley guinea pigs weighing 500 to 700 g (SLC) were actively sensitized by the intraperitoneal injection of OA (5 μg) and alum (1 mg) in saline (0.5 ml). Sensitizations were performed three times at 7- to 12-day intervals.

Antigen-Induced Bronchoconstriction in Anesthetized Sensitized Guinea Pigs.

Ten days after the final sensitization, the animals were anesthetized with urethane (1.2–1.5 g/kg i.p.). The trachea was cannulated to allow mechanical ventilation (Harvard 683 rodent ventilator; Harvard Bioscience, South Natick, MA) at 60 strokes/min with a stroke volume of 1 ml/100 g of body weight. The animals were secured in the plethysmograph box connected to the transducer and the ventilator just mentioned for measurement of the airway resistance. Bronchoconstriction was induced by 0.5% OA inhalation for 5 min with an ultrasonic nebulizer (NE-U12; Omron, Kyoto, Japan). Lung resistance (Rl) was monitored and calculated for 15 min after the initiation of OA inhalation with a pulmonary function analyzer (model P; Buxco Electronics Inc., Sharon, CT). Each compound was administered orally 30 min before the antigen challenge.

Antigen-Induced Plasma Leakage in Sensitized Guinea Pigs.

Ten to 14 days after the final sensitization, the animals were pretreated with an antihistamine agent, pyrilamine (2 mg/kg i.v.), to avoid anaphylactic shock. Ten minutes later, they were placed in an exposure chamber connected to the output of a glass nebulizer (Kinoshita, Tokyo, Japan) driven by compressed air at 100 ml/s. The nebulizer chamber was filled with 0.5% OA (control and compound-treated groups) or saline (saline group), and antigen inhalation was performed for 30 min. To evaluate the plasma leakage, Evans blue (40 mg/kg i.v.) was injected 5 min before the challenge. Each compound was administered orally 30 min before the antigen inhalation.

Thirty minutes after the end of inhalation, the animals were sacrificed by cervical dislocation and exsanguinated by cutting the cervical blood vessels. Bronchial tissue samples were taken and the Evans blue dye was extracted and quantified as previously described (Katayama et al., 1978).

Antigen-Induced Cell Infiltration into the Lungs in Sensitized Guinea Pigs.

The sensitized guinea pigs were pretreated with pyrilamine and challenged with antigen (0.5% OA) for 30 min by the same method as was used in the leakage experiments.

Twenty-four hours after the antigen challenge, the guinea pigs were sacrificed and the lungs were lavaged three times with 10 ml of saline containing heparin (1 unit/ml). The recovered lavage samples were divided into three fractions. One fraction was placed into boiled water for 2 min, and then cooled in ice and centrifuged at 10,000gfor 30 min at 4°C. The cAMP contents of the supernatant (pmol/106 cells) were measured using a cAMP enzyme immunoassay system (Amersham Pharmacia Biotech, Uppsala, Sweden). Another fraction was cooled on ice, and centrifuged at 200g for 10 min at 4°C. The supernatant peroxidase activity of BAL fluids and the intracellular peroxidase activity of infiltrated leukocytes were measured by the spectrophotometric reduction of cytochrome c. The data were indicated as the optical density value at 550 nM (O.D.550) value/106 cells.

The other fraction was used for counting the number of leukocytes. The total number of leukocytes was counted using a cell counter (Celltac-α; Nippon Kohden, Tokyo, Japan). At least 300 cells were differentiated according to standard morphological criteria (eosinophils, mononuclear cells, and neutrophils) using Cytospin preparations stained with Diff-Quik (International Reagents Corp.). In addition, basal cell accumulation was determined in saline-challenged animals. For each treatment group, results were expressed as the percentage inhibition of cell influx compared with that in the vehicle control group. Compounds were administered orally 30 min before and 3 h after the challenge.

Antigen-Induced AHR and Cell Infiltration in Sensitized Guinea Pigs.

The sensitization method described above could not elicit the apparent AHR in guinea pigs (data not shown), and so we carried out the evaluation using a different method of sensitization and challenge.

Male Hartley guinea pigs were actively sensitized by intraperitoneal injection of OA (10 μg) and alum (10 mg) in saline (0.5 ml). Seven days later, 5% OA inhalation for 5 min was performed three times at 7- to 14-day intervals. Seven days after the final inhalation, the animals were pretreated with pyrilamine (2 mg/kg i.v.), and 10 min later, they were challenged by the inhalation of 0.5% OA for 30 min by the same method as is described above. Twenty-four hours after the challenge, the animals were anesthetized with urethane and the trachea was cannulated to allow mechanical ventilation at 60 strokes/min with a stroke volume of 10 ml/kg of body weight. After galamine was injected (1 mg/kg i.v.) to eliminate spontaneous respiration and stabilize the ventilation, the airway reactivity was determined by subsequent inhalations of saline and each concentration of ACh (1, 3, 10, 30, and 100 mg/ml in saline) using a nebulizer (NE-U12; Omron). Intra-airway pressure (PIP; cm H2O) was monitored with a low-pressure transducer (TP-101; Nihon Kohden) connected to the sidearm of a tracheal cannula. Data were measured using carrier-amplitude amplifiers (AP-620G; Nihon Kohden) and recorded on a Mini-polygraph (RM-6100; Nihon Kohden) and on a Macintosh computer by a MacLab/8 software system (MKIII; AD Instruments, Castle Hill, Australia). The change in PIP induced by ACh inhalation was measured to represent the airway reactivity, and PIP at the basal level was given by the inhaled saline. Data were expressed as the concentrations at which PIP reached a value two times the basal level (log10PC200). Five minutes after the highest concentration (100 mg/ml) of ACh inhalation, the lungs were lavaged three times with 10 ml of saline containing heparin (1 unit/ml) through the cannula. The lavage fluid was centrifuged at 200g for 10 min at 4°C, and the cell pellet was resuspended in 1 ml of saline. The total leukocyte number was counted with Celltac-α, and the cell differentiation was determined by the method described above. Compounds were administered orally 30 min before and 3 h after the antigen challenge.

Superoxide Production from Isolated Guinea Pig Eosinophils.

Guinea pig eosinophils were isolated by a previously reported method (Souness et al., 1995) and the discontinuous density gradient method. Eosinophils (1 × 106/ml) were suspended in Hanks' balanced salt solution containing 20 mM HEPES, 0.1% gelatin, and 150 μM cytochrome c. Superoxide generation was initiated by the addition of fMLP (50 nM), and was measured by the spectrophotometric reduction of cytochrome c. Results were determined by the change in the absorbance at 550 nm over 40 min after the initiation.

LTD4-Induced Constriction of Isolated Bronchial Smooth Muscle from Guinea Pigs.

The method of isolating tracheal smooth muscle was essentially the same as that described previously (Baba et al., 1986). Guinea pig trachea was transferred into cold oxygenated Krebs' solution, and the connective tissue was carefully cleaned. The trachea was opened by a longitudinal cut through the cartilaginous region diametrically opposite the tracheal smooth muscle, and divided into four strips containing five or six cartilages. A strip was suspended vertically under 1-g tension in Krebs' solution (37°C, pH = 7.4) continuously gassed with 5% CO2and 95% O2 in a 10-ml organ bath. Carbachol (3 μM) was added to the bath, and after the contractile response had reached a plateau the tissues were washed four times over a 15-min period and allowed to equilibrate for a further 30 min.

Relaxation activity was assessed in tracheas precontracted with LTD4, which was determined as the concentration indicating the submaximal contraction from the preliminary experiment (data not shown). Following the equilibration period, the bronchial strip was contracted with 100 nM LTD4. After the contraction plateau was reached, the concentration-response curves for YM976 and the other compounds were established. After the maximal effect of each concentration was obtained, isoproterenol (1 μM) was added to determine the maximal relaxation response.

LTD4-Induced Bronchospasm in Anesthetized Guinea Pigs in Vivo.

Male Hartley guinea pigs were anesthetized with urethane. The trachea was cannulated to allow mechanical ventilation at 60 strokes/min with a stroke volume of 10 ml/kg of body weight. The changes in airway resistance were measured with the Buxco pulmonary function analyzer.

A cannula was tied into the right jugular vein to allow the injection of spasmogen solution. After the connection of the animals to ventilators, histamine (3 μg/kg) was injected intravenously twice with a 5-min interval to stabilize the responses. After the recovery to the basal level of airway resistance, LTD4 (0.3 μg/kg) was intravenously injected, and the change of Rl was monitored from 2 min before to 5 min after the LTD4injection. YM976 and the other compounds were orally administered 30 min before the first injection of histamine. Airway contraction was determined as the change from the basal value.

Data Analysis.

Data were expressed as the mean ± S.E. or means with 95% confidence limits. Statistical significance of differences between means of groups was determined by Dunnett's multiple range test or Student's t test, and probabilities of <0.05 were considered significant. Concentrations or doses causing 50 or 30% inhibition were determined by nonlinear curve fitting using a SAS system (SAS Institute Inc., Cary, NC).

Results

Effects on Antigen-Induced Bronchoconstriction.

Aerosolized OA caused an immediate bronchoconstriction, which peaked within 15 min in sensitized guinea pigs. Inhaled antigen increased Rl from 0.157 to 0.499 cm H2O/ml/s in the OA group (n = 7). On the other hand, in the saline group, Rl increased from 0.163 to 0.174 cm H2O/ml/s (n = 6). YM976 showed a dose-dependent inhibition of Rl increases, with an ED50 value of 7.3 mg/kg p.o. (Table 1; Fig.1). Rolipram and theophylline also dose dependently inhibited the bronchoconstriction with ED50 values of 7.7 and 67 mg/kg, respectively, whereas prednisolone did not cause suppression even at 100 mg/kg p.o. RP73401, one of the strongest PDE4 inhibitors, showed 68% inhibition at 1 mg/kg p.o.

View this table:
  • View inline
  • View popup
Table 1

Doses of YM976, rolipram, theophylline, and prednisolone effective against antigen-induced immediate bronchoconstriction, airway plasma leakage, and lung eosinophil infiltration in sensitized guinea pigs

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Effects of YM976, rolipram, theophylline, prednisolone, and RP73401 on antigen-induced bronchoconstriction in sensitized guinea pigs. Each compound was administered orally 30 min before OA inhalation. Results are represented as the maximal Rl value during 15 min monitored after OA inhalation. Data are expressed as the mean ± S.E. of five to eight animals.###p < 0.001, significant difference between the saline and OA groups (Student's t test). *p < 0.05 and ***p < 0.001: significant differences between the OA group and the relevant compound treatment group (Dunnett's multiple range test).

Effects on Antigen-Induced Airway Plasma Leakage.

Antigen inhalation by the sensitized guinea pigs significantly increased airway plasma leakage, which was determined as the amount of dye (Evans blue) extravasation. In the saline group, the amount of dye was between 56 and 72 ng/mg tissue, and in the OA group, it was between 206 and 244 ng/mg tissue. YM976 dose dependently suppressed the increased extravasation of dye with an ED50 value of 5.7 mg/kg p.o. (Table 1; Fig. 2). Rolipram and theophylline also inhibited the extravasation, with oral ED50 values of 3.0 and 16 mg/kg, respectively. On the other hand, prednisolone failed to show significant inhibition up to 100 mg/kg p.o., and the maximal inhibition ratio was 46%.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

Effects of YM976, rolipram, theophylline, and prednisolone on increases in antigen-induced microvascular permeability in sensitized guinea pigs. Each compound was administered orally 30 min before OA inhalation. Extravasation of Evans blue dye in intrapulmonary airways was measured. Data are expressed as the mean ± S.E. of five to seven animals. ##p < 0.01; and###p < 0.001, significant differences between the saline and OA groups (Student's t test). *p < 0.05, **p < 0.01, and ***p < 0.001, significant differences between the OA group and the relevant compound treatment group (Dunnett's multiple range test).

Effects on Antigen-Induced Cell Infiltration into the Lungs.

In the guinea pigs, OA inhalation caused increases in total leukocyte numbers in BAL fluid 24 h after the challenge. YM976 at oral doses of 0.3 to 10 mg/kg significantly and dose dependently inhibited eosinophil infiltration, with an ED50 of 1.0 mg/kg (Table 1; Fig. 3). Rolipram and prednisolone also dose dependently inhibited the cell infiltration, with oral ED50 values of 3.6 and 5.1 mg/kg, respectively. Theophylline did not achieve 50% suppression on the infiltration up to 100 mg/kg p.o.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

Effects of YM976, rolipram, theophylline, and prednisolone on antigen-induced inflammatory cell infiltration into the lungs in sensitized guinea pigs. Each compound was administered orally 30 min before and 3 h after antigen challenge. Data are expressed as the mean ± S.E. of five to seven animals.##p < 0.01 and###p < 0.001, significant differences between the saline and OA groups (Student's t test). *p < 0.05, **p < 0.01, and ***p < 0.001, significant differences between the OA group and the relevant compound treatment group (Dunnett's multiple range test).

In the same experiment, we measured the peroxidase activities and cAMP contents to examine the infiltrated inflammatory cell activation. YM976 inhibited the peroxidase activity in the supernatant of BAL fluid and elevated the intracellular peroxidase activity of the infiltrated leukocytes. YM976 also increased intracellular cAMP contents of the infiltrated cells (Fig. 4).

Figure 4
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4

Effect of YM976 on peroxidase activity and intracellular cAMP content in antigen-induced cell infiltration experiments. Peroxidase activity was expressed as the reduction of cytochrome c (O.D. values at 550 nM). A, peroxidase activity in the supernatant of BAL fluid containing 106cells. B, intracellular peroxidase activity of the infiltrated cells. C, intracellular cAMP content of the infiltrated cells (106cells). Cell infiltration into the lungs was induced by antigen inhalation in sensitized guinea pigs. YM976 was administered orally 30 min before and 3 h after antigen challenge. Data are expressed as the mean ± S.E. of five to seven animals.###p < 0.001, difference between the saline and OA groups (Student's t test). *p < 0.05, significant difference between OA group and the relevant compound treatment group (Dunnett's multiple range test).

Antigen-Induced AHR and Cell Infiltration.

Sensitization with one intraperitoneal injection and three inhalations of antigen resulted in the induction of AHR to ACh. YM976 was orally administered 30 min before and 3 h after the final antigen inhalation, and it dose dependently and significantly shifted the PIP curve to the right between 1 and 10 mg/kg p.o. (Fig. 5). YM976 and rolipram dose dependently increased the PC200 value, with oral ED50 values of 0.52 and 2.7 mg/kg, respectively (Table 2). Prednisolone increased the PC200 value, but not to a statistically significant extent, with an ED50 value of 24 mg/kg p.o.. In the same experiment, YM976, rolipram, and prednisolone also dose dependently inhibited the eosinophil infiltration, with ED50 values of 1.8, 8.6, and 16 mg/kg, respectively (Table 2).

Figure 5
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5

Effect of YM976 on antigen-induced airway hyperreactivity (A and B) and inflammatory cell infiltration (C). Sensitized guinea pigs were exposed to antigen inhalation for 30 min. Twenty-four hours later, airway reactivity was determined by subsequent inhalation of saline and various concentrations of ACh (1, 3, 10, 30, and 100 mg/ml) under anesthesia. Five minutes after 100 mg/ml ACh inhalation, the lungs were lavaged. YM976 was administered orally 30 min before and 3 h after inhalation. Data are expressed as the mean ± S.E. #p < 0.05,##p < 0.01, and###p < 0.001, significant difference between the saline and OA groups (Student's t test). *p < 0.05, **p < 0.01, and ***p < 0.001, significant differences between the OA group and the relevant compound treatment group (Dunnett's multiple range test, n = 9–10).

View this table:
  • View inline
  • View popup
Table 2

Doses of YM976, rolipram, theophylline, and prednisolone effective against antigen-induced airway hyperreactivity and inflammatory cell infiltration in guinea pigs

Inhibitory Effects on Superoxide Generation from Isolated Eosinophils.

Results were expressed as the concentrations that induced 30% inhibition (EC30), because it was reported that the superoxide generation from guinea pig eosinophils stimulated by fMLP and zymosan was inhibited by a maximum of 60% by various PDE4 inhibitors (Barnette et al., 1995). YM976, rolipram, and RP73401 dose dependently inhibited fMLP-induced superoxide generation, with EC30 values of 83, 500, and 7.6 nM, respectively (Table 3).

View this table:
  • View inline
  • View popup
Table 3

In vitro effects of YM976, rolipram, RP73401, and theophylline on superoxide generation from guinea pig eosinophils and relaxation activity on precontacted guinea pig tracheal smooth muscle

Relaxation Effects on LTD4-Induced Tracheal Contraction in Vitro.

LTD4 at 30 nM induced the contraction of tracheal smooth muscle in vitro. YM976 elicited concentration-dependent relaxation, with an EC50value of 370 nM (Fig. 6; Table 3). Rolipram and RP73401 showed potent relaxation effects, with EC50 values of 50 and 6.8 nM, respectively. Theophylline also relaxed the tracheal contraction, but the effect was much weaker (EC50 = 5000 nM) than that of the other compounds.

Figure 6
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6

In vitro relaxation activities of YM976 (●), rolipram (■), RP73401 (○), and theophylline (▾). Relaxation activity was assessed in tracheas precontracted with LTD4. Following the equilibration period, the bronchial strip was contracted with 100 nM LTD4. After the contraction plateau was reached, the concentration-response curves for YM976 and the other compounds were established. After the maximal effect of each concentration was obtained, isoproterenol (1 pM) was added to determine the maximal relaxation response.

Effects on LTD4-Induced Bronchospasm in Vivo.

Intravenous LTD4 injection (0.3 μg/kg) produced an evident increase in Rl, which reached 0.256 cm H2O/ml/s. YM976 showed little suppression of bronchospasm induced by LTD4 whose inhibitory ratio is 28% at 30 mg/kg p.o. (Fig. 7). On the other hand, rolipram, theophylline, and RP73401 significantly inhibited the response at 30, 100, and 3 mg/kg p.o., respectively.

Figure 7
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 7

Dilatory effects on LTD4-induced bronchospasm in guinea pigs. LTD4 was injected intravenously at a dose of 0.3 pg/kg. The mean of the Rl basal values was 0.102 ± 0.003 cm H2O/ml/s, and the differences among the groups were not significant (p > 0.38, one-way ANOVA). All other compounds were administered orally 30 min before the first histamine injection. Data are expressed as mean ± S.E. of changes from the basal value of five to six animals. **p < 0.01 and ***p < 0.001, significant differences from the control group and the relevant compound treatment group (Dunnett's multiple range test). Theo, theophylline.

Discussion

Much evidence has appeared in the literature suggesting that PDE4 inhibitors might become potent novel therapeutic agents for bronchial asthma (Barnette, 1999). Indeed, the primary target disease of most PDE4 inhibitors under clinical development is bronchial asthma. Unfortunately, some existing PDE4 inhibitors tend to cause emesis at the same doses that cause anti-inflammatory effects (Heaslip and Evans, 1995), and the efficacy might be limited. A new PDE4 inhibitor is required that can provide therapeutic benefit without causing emesis. In our previous report (Aoki et al., 2000a), we indicated that YM976 was an orally active and selective PDE4 inhibitor with an apparent dissociation from emetic activity. In the present study, we evaluated the antiasthmatic effects of YM976 on some experimental guinea pig models in which symptoms were elicited by antigen inhalation.

YM976 suppressed antigen-induced immediate bronchoconstriction in a dose-dependent manner. To investigate the mechanism of action, the bronchodilator effect of YM976 was assessed in vitro and in vivo. YM976 exerted only a weak relaxation of precontracted smooth muscle (EC50 = 370 nM), although it effectively suppressed eosinophil superoxide generation (EC50= 83 nM), which could have induced the bronchoconstriction (Sagai et al., 1996; De Boer et al., 1998). Rolipram also inhibited antigen-induced bronchoconstriction. However, unlike YM976, rolipram showed a potent relaxation of precontracted bronchial smooth muscle in vitro (EC50 = 50 nM) compared with the inhibitory activity of superoxide generation (EC50 = 500 nM). Indeed, rolipram significantly inhibited LTD4-induced bronchospasm potently in guinea pigs at 30 mg/kg p.o., whereas YM976 showed slight inhibition for the bronchospasm. RP73401 also showed a potent in vivo inhibition of bronchoconstriction induced by antigen and LTD4(ED50 < 3 mg/kg p.o.) and a strong relaxation effect in vitro (EC50 = 6.8 nM). These results were supported by the report showing that rolipram and RP73401 relaxed guinea pig isolated tracheal preparations at a basal tone, and showed in vivo bronchodilator effects (Raeburn et al., 1994; Turner et al., 1996). PDE4 inhibitors were reported to inhibit the release of spasmogens, such as LTs (Heaslip et al., 1992; Howell et al., 1994) and thromboxane A2 (Uhlig et al., 1997). Indeed, YM976 and rolipram inhibited fMLP-induced LTC4/D4/E4release from human eosinophils with IC50 values of 3.9 and 12 nM, respectively (M. Aoki, unpublished data, 2000). It is most likely that YM976 suppresses antigen-induced bronchoconstriction through inhibition of the spasmogen release from the leukocytes rather than by any direct relaxation effect. On the other hand, rolipram and RP73401 may show the inhibition on the bronchoconstriction via the direct dilator activity as well as the inhibition of leukocytes.

Airway edema resulting from plasma leakage induced by antigen is an important inflammatory event in asthma (Persson, 1988). YM976 and rolipram dose dependently inhibited antigen-induced plasma leakage. Although the inhibitory mechanisms of YM976 have not been elucidated, rolipram is reported to inhibit platelet-activating factor-induced plasma leakage in guinea pigs at least partially by inhibiting contraction of the endothelial cells (Ortiz et al., 1993).

Accumulation in the lungs of inflammatory cells such as eosinophils is also known to be an important event in the development of bronchial asthma. The drugs that can inhibit inflammatory cell accumulation in the lungs are useful therapeutic agents for bronchial asthma. We assessed the effects of YM976 on the antigen-induced cell infiltration into the lungs in the sensitized guinea pigs. YM976 markedly decreased the eosinophil infiltration into the lungs 24 h after the challenge with an ED50 value of 1.0 mg/kg p.o. The precise mechanisms by which YM976 inhibits eosinophil infiltration are still unclear. However, the pharmacological actions of PDE4 inhibitors described in numerous studies could explain the inhibitory mechanisms of YM976. PDE4 inhibitors can act in several ways to reduce cell infiltration into the lungs: 1) suppressing eosinophil chemotaxis (Alves et al., 1996); 2) decreasing the survival of eosinophils (Hallsworth et al., 1996); 3) inhibiting the differentiation of eosinophil precursors such as IL-5 inhibition (Kaminuma et al., 1996); 4) suppressing other cell types such as monocytes, which can release mediators acting as chemoattractants for eosinophils (Nourshargh., 1993); 5) inhibiting the expression of adhesion molecules (Berends et al., 1997); and 6) inhibiting cytokine production and T-cell proliferation (Giembycz et al., 1996). Pulmonary vasculature and endothelium are other potential sites of action. The endothelial cells express PDE4 (Lugnier and Schini, 1990) and increased levels of cAMP reduce the expression of the adhesion molecules (Blease et al., 1998). YM976 inhibits tumor necrosis factor-α production (Aoki et al., 2000b), which can induce intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 expression (Wellicome et al., 1990). However, it is not immediately obvious which mechanism is the most likely to be of primary importance, since PDE4 has been identified in many kinds of inflammatory cells.

Recent clinical studies with humanized monoclonal antibodies to IL-5 demonstrated that blocking IL-5 had no effects on immediate or late responses to allergens, or on AHR, although it reduced eosinophil recruitment into the airways (Barnes, 1999). These results suggested that the inhibition of eosinophil infiltration itself was not sufficient to reduce asthma symptoms significantly, although eosinophils were strongly related to the development of asthma. The inhibition of functions of remaining eosinophils in the airway may be also necessary to exert antiasthmatic effects. Therefore, we examined the effect of YM976 on the activation of eosinophils in vivo and in vitro. In the cell infiltration experiment using guinea pigs, YM976 suppressed the peroxidase activity in the supernatants of BAL fluid derived from infiltrated leukocytes, including eosinophils. Simultaneously, YM976 increased the intracellular peroxidase activity of the infiltrated leukocytes. Since YM976 increased the cAMP contents of the infiltrated cells, it is likely that YM976 inhibited peroxidase release from leukocytes by the elevation of intracellular cAMP. As described above, an in vitro experiment indicated that YM976 suppressed the eosinophil activation. These results suggested that YM976 suppressed not only eosinophil infiltration into the lungs but also the activation of eosinophils in the airways.

YM976 inhibited the antigen-induced AHR to ACh in guinea pigs, with an ED50 value of 0.52 mg/kg p.o. Since YM976 had no effect on the bronchoconstriction induced by ACh, even at 10 mg/kg p.o. (data not shown), the inhibition of AHR was not due to antagonism toward ACh. At the same time, YM976 also suppressed the eosinophil infiltration into the lungs. AHR is induced by the activation of infiltrated eosinophils into the airway (Venge, 1990). Infiltrated and activated eosinophils can induce epithelial damage by the release of cytotoxic cationic proteins, such as eosinophil peroxidase or eosinophil cationic protein. Thus, the prevention of antigen-induced eosinophilic inflammation by YM976 may underlie the reduction in the development of AHR. Another possible action site for PDE4 inhibitors is the sensory nerves. Rolipram inhibited the excitatory noncholinergic neurotransmission in guinea pig bronchi (Undem et al., 1994), and augmented the nonadrenergic and noncholinergic relaxation of human isolated bronchus (Fernandes et al., 1994). These effects may be related to the inhibition of the release of bronchoconstrictor neuropeptides such as Substance P from the sensory nerve endings. This may also contribute to the anti-inflammatory effects of PDE4 inhibitors since Substance P is a chemotactic factor for eosinophils (Kudlacz and Kippenberg, 1994).

As summarized, YM976 prevented antigen-induced immediate bronchoconstriction, airway edema, eosinophil infiltration, and AHR in guinea pigs. Furthermore, YM976 also showed in vitro and in vivo inhibition on the activation of eosinophils. Since YM976, unlike rolipram and RP73401, had a weak direct bronchodilator effect, these antiasthmatic effects have contributed to anti-inflammatory effects such as the suppression of inflammatory cell functions. YM976 may, through its anti-inflammatory activity, have a potential therapeutic value in the treatment of bronchial asthma.

Footnotes

  • Send reprint requests to: Dr. Motonori Aoki, International Clinical Development Department, Yamanouchi Pharmaceutical Co., Ltd., 17-1 Hasune 3-Chome, Itabashi-ku, Tokyo, 174-8612, Japan. E-mail: aokim{at}yamanouchi.co.jp

  • Abbreviations:
    PDE4
    phosphodiesterase type 4
    DMSO
    dimethyl sulfoxide
    OA
    ovalbumin
    ACh
    acetylcholine
    fMLP
    formyl-methionyl-leucyl-phenylalanine
    LTD4
    leukotriene D4
    Rl
    lung resistance
    AHR
    airway hyperreactivity
    BAL
    bronchoalveolar lavage
    PIP
    intra-airway pressure
    IL-5
    interleukin-5
    RP73401
    3-cyclopentyloxy-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide
    • Received October 19, 2000.
    • Accepted December 13, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Alves AC,
    2. Pires AL,
    3. Cruz HN,
    4. Serra MF,
    5. Diaz BL,
    6. Cordeiro RS,
    7. Lagente V,
    8. Martins MA
    (1996) Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro. Eur J Pharmacol 312:89–96.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Aoki M,
    2. Fukunaga M,
    3. Kitagawa M,
    4. Hayashi K,
    5. Morokata T,
    6. Ishikawa G,
    7. Kubo S,
    8. Yamada T
    (2000a) Effect of a novel anti-inflammatory compound, YM976, on antigen-induced eosinophil infiltration into the lungs in rats, mice and ferrets. J Pharmacol Exp Ther 295:1149–1155.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Aoki M,
    2. Kobayashi M,
    3. Ishikawa J,
    4. Saita Y,
    5. Terai Y,
    6. Takayama K,
    7. Miyata K,
    8. Yamada T
    (2000b) A novel phosphodiesterase type 4 inhibitor, YM976 (4-(3-chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with little emetogenic activity. J Pharmacol Exp Ther 295:255–260.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Baba K,
    2. Satake T,
    3. Takagi K,
    4. Tomita T
    (1986) Effects of verapamil on the response of the guinea-pig tracheal muscle to carbachol. Br J Pharmacol 88:441–449.
    OpenUrlPubMed
  5. ↵
    1. Barnes PJ
    (1999) Therapeutic strategies for allergic diseases. Nature (Lond) 402 (Suppl S) B31–B38.
    OpenUrlPubMed
  6. ↵
    1. Barnette MS
    (1999) Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog Drug Res 53:193–229.
    OpenUrlPubMed
  7. ↵
    1. Barnette MS,
    2. Manning CD,
    3. Cieslinski LB,
    4. Burman M,
    5. Christensen SB,
    6. Torphy TJ
    (1995) The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J Pharmacol Exp Ther 273:674–679.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Berends C,
    2. Dijkhuizen B,
    3. de Monchy JG,
    4. Dubois AE,
    5. Gerritsen J,
    6. Kauffman HF
    (1997) Inhibition of PAF-induced expression of CD11b and shedding of L-selectin on human neutrophils and eosinophils by the type IV selective PDE inhibitor, rolipram. Eur Respir J 10:1000–1007.
    OpenUrlAbstract
  9. ↵
    1. Bernareggi MM,
    2. Belvisi MG,
    3. Patel H,
    4. Barnes PJ,
    5. Giembycz MA
    (1999) Anti-spasmogenic activity of isoenzyme-selective phosphodiesterase inhibitors in guinea-pig trachealis. Br J Pharmacol 128:327–336.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Blease K,
    2. Burke-Gaffney A,
    3. Hellewell PG
    (1998) Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br J Pharmacol 124:229–237.
    OpenUrlCrossRefPubMed
  11. ↵
    1. De Boer J,
    2. Pouw FMH,
    3. Zaagsma J,
    4. Meurs H
    (1998) Effects of endogenous superoxide anion and nitric oxide on cholinergic constriction of normal and hyperreactive guinea pig airways. Am J Respir Crit Care Med 158:1784–1789.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Fernandes LB,
    2. Ellis JL,
    3. Undem BJ
    (1994) Potentiation of nonadrenergic noncholinergic relaxation of human isolated bronchus by selective inhibitors of phosphodiesterase isozymes. Am J Respir Crit Care Med 150:1384–1390.
    OpenUrlPubMed
  13. ↵
    1. Giembycz MA,
    2. Dent G
    (1992) Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of bronchial asthma. Clin Exp Allergy 22:337–344.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Giembycz MA,
    2. Corrigan CJ,
    3. Seybold J,
    4. Newton R,
    5. Barnes PJ
    (1996) Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: Role in regulating proliferation and the biosynthesis of interleukin-2. Br J Pharmacol 118:1945–1958.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Hallsworth MP,
    2. Giembycz MA,
    3. Barnes PJ,
    4. Lee TH
    (1996) Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF. Br J Pharmacol 117:79–86.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Heaslip RJ,
    2. Evans DY
    (1995) Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur J Pharmacol 286:281–290.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Heaslip RJ,
    2. Hardysh BA,
    3. Berkenkopf JW,
    4. Weichman BM
    (1992) Effects of selective phosphodiesterase inhibitors on antigen-induced leukotriene release and leukotriene-dependent tracheal muscle contraction. Am Rev Respir Dis 145:A859.
    OpenUrl
  18. ↵
    1. Howell RE,
    2. Sickels BD,
    3. Woeppel SL
    (1994) Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs. J Pharmacol Exp Ther 264:609–615.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Kaminuma O,
    2. Mori A,
    3. Suko M,
    4. Kikkawa H,
    5. Ikezawa K,
    6. Okudaira H
    (1996) Interleukin-5 production by peripheral blood mononuclear cells of asthmatic patients is suppressed by T-440: Relation to phosphodiesterase inhibition. J Pharmacol Exp Ther 279:240–246.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Katayama S,
    2. Shionoya H,
    3. Ohtake S
    (1978) A new method for extraction of extravasated dye in the skin and the influence of fasting stress on passive cutaneous anaphylaxis in guinea pigs and rats. Microbiol Immunol 22:89–101.
    OpenUrlPubMed
  21. ↵
    1. Kudlacz EM,
    2. Knippenberg RW
    (1994) In vitro and in vivo effects of tachykinins on immune cell function in guinea pig airways. J Neuroimmunol 50:119–125.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Lugnier C,
    2. Schini VB
    (1990) Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells. Biochem Pharmacol 39:75–84.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Nourshargh S
    (1993) Mechanisms of neutrophil and eosinophil accumulation in vivo. Am Rev Respir Dis 148:S60–S64.
    OpenUrlPubMed
  24. ↵
    1. Ortiz JL,
    2. Cortijo J,
    3. Valles JM,
    4. Bou J,
    5. Morcillo EJ
    (1993) Rolipram inhibits airway microvascular leakage induced by platelet-activating factor, histamine and bradykinin in guinea-pigs. J Pharm Pharmacol 45:1090–1092.
    OpenUrlPubMed
  25. ↵
    1. Persson CG
    (1988) Plasma exudation and asthma. Lung 166:1–23.
    OpenUrlPubMed
  26. ↵
    1. Raeburn D,
    2. Underwood SL,
    3. Lewis SA,
    4. Woodman VR,
    5. Battram CH,
    6. Tomkinson A,
    7. Sharma S,
    8. Jordan R,
    9. Souness JE,
    10. Webber SE,
    11. et al.
    (1994) Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor. Br J Pharmacol 113:1423–1431.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Sagai M,
    2. Furuyama A,
    3. Ichinose- T
    (1996) Biological effects of diesel exhaust particles (DEP). III. Pathogenesis of asthma like symptoms in mice. Free Radic Biol Med 21:199–209.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Souness JE,
    2. Maslen C,
    3. Webber S,
    4. Foster M,
    5. Raeburn D,
    6. Palfreyman MN,
    7. Ashton MJ,
    8. Karlsson JA
    (1995) Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: Comparison with rolipram. Br J Pharmacol 115:39–46.
    OpenUrlPubMed
  29. ↵
    1. Turner CR,
    2. Cohan VL,
    3. Cheng JB,
    4. Showell HJ,
    5. Pazoles CJ,
    6. Watson JW
    (1996) The in vivo pharmacology of CP-80,633, a selective inhibitor of phosphodiesterase 4. J Pharmacol Exp Ther 278:1349–1355.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Uhlig S,
    2. Featherstone RL,
    3. Held HD,
    4. Nusing R,
    5. Schudt C,
    6. Wendel A
    (1997) Attenuation by phosphodiesterase inhibitors of lipopolysaccharide-induced thromboxane release and bronchoconstriction in rat lungs. J Pharmacol Exp Ther 283:1453–1459.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Undem BJ,
    2. Meeker SN,
    3. Chen J
    (1994) Inhibition of neurally mediated nonadrenergic, noncholinergic contractions of guinea pig bronchus by isozyme-selective phosphodiesterase inhibitors. J Pharmacol Exp Ther 271:811–817.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Venge P
    (1990) What is the role of the eosinophil? Thorax 45:161–163.
    OpenUrlFREE Full Text
  33. ↵
    1. Wellicome SM,
    2. Thornhill MH,
    3. Pitzalis C,
    4. Thomas DS,
    5. Lanchbury JSS,
    6. Panayi GS,
    7. Haskard DO
    (1990) A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1, or lipopolysaccharide. J Immunol 144:2558–2565.
    OpenUrlAbstract
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 297 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 297, Issue 1
1 Apr 2001
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Antiasthmatic Effect of YM976, a Novel PDE4 Inhibitor, in Guinea Pigs
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Antiasthmatic Effect of YM976, a Novel PDE4 Inhibitor, in Guinea Pigs

Motonori Aoki, Satoshi Yamamoto, Miki Kobayashi, Keiko Ohga, Hiroyuki Kanoh, Keiji Miyata, Kazuo Honda and Toshimitsu Yamada
Journal of Pharmacology and Experimental Therapeutics April 1, 2001, 297 (1) 165-173;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Antiasthmatic Effect of YM976, a Novel PDE4 Inhibitor, in Guinea Pigs

Motonori Aoki, Satoshi Yamamoto, Miki Kobayashi, Keiko Ohga, Hiroyuki Kanoh, Keiji Miyata, Kazuo Honda and Toshimitsu Yamada
Journal of Pharmacology and Experimental Therapeutics April 1, 2001, 297 (1) 165-173;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cinnabarinic acid protects against NAFLD
  • SGLT-2 inhibition exacerbates hepatic encephalopathy
  • TK1 Mediates the Antitumor Activity of UNM and CCB
Show more Gastrointestinal, Hepatic, Pulmonary, and Renal

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics